Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K / AKT pathway
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8146 ↗At a glance
Journal article in Phytotherapy Research, 2024. Written by Hong Wu and 7 co-authors. Institution: Department of Research, Guangxi Medical University Cancer Hospital, Nanning, China. Major MEDLINE topics: Macrophages, Osteosarcoma, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt. Cited 30 times so far (Crossref); 47 references. Funded by: Innovation Project of Guangxi Graduate Education.
Abstract (original language)
Osteosarcoma is a common malignant bone tumour characterised by an aggressive metastatic potential. The tumour microenvironment, particularly the M2‐polarised macrophages, is crucial for tumour progression. Cucurbitacin B (CuB), a triterpenoid derivative, is recognised for its anti‐inflammatory and antitumour properties. This study investigates CuB and its effect on M2 macrophage differentiation and osteosarcoma progression, aiming to contribute to new treatment strategies. In vitro, THP‐1 monocytes were stimulated with PMA, IL‐13 and IL‐4 to induce differentiation into M2 macrophages. Additionally, the influence of CuB on the proliferation, migration and invasion of osteosarcoma cells in the context of M2 macrophages was scrutinised. Crucial signalling pathways, especially the PI3K/AKT pathway, affected by CuB were identified and validated. In vivo, the osteosarcoma model was employed to gauge the effects of CuB on tumour weight, lung metastasis, angiogenesis, cell proliferation and M2 macrophage markers. The results showed that CuB inhibited M2 macrophage differentiation, leading to reduced proliferation, migration and invasion of osteosarcoma cells. CuB manifested an inhibitory effect on the PI3K/AKT pathway during the differentiation of M2 macrophages. In mouse models, CuB markedly reduced the tumour weight and the number of lung metastases. It also reduced the expression of angiogenesis and cell proliferation markers in tumour tissues, decreased the quantity of M2 macrophages and their associated markers and pathway proteins. In conclusion, CuB impedes osteosarcoma progression by inhibiting M2 macrophage differentiation via the PI3K/AKT pathway, presenting the potential for therapeutic advancements in osteosarcoma treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Research, Guangxi Medical University Cancer Hospital, Nanning, China.
- Department of Bone and Joint Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, China.
- Department of Orthopaedics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
ORCID profiles: Hui Wang
Funding
- Innovation Project of Guangxi Graduate Education
Cite
APA
Wu, H., Ma, T., He, M., Xie, W., Wang, X., Lu, L., Wang, H., & Cui, Y. (2024). Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K / AKT pathway. Phytotherapy Research. https://doi.org/10.1002/ptr.8146
Vancouver
Wu H, Ma T, He M, Xie W, Wang X, Lu L, et al. Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K / AKT pathway. Phytotherapy Research. 2024. doi:10.1002/ptr.8146
BibTeX
@article{Wu2024,
author = {Wu, Hong and Ma, Tianjun and He, Mei and Xie, Wenkai and Wang, Xueyan and Lu, Liuping and Wang, Hui and Cui, Ying},
title = {Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K / AKT pathway},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8146}
}
EUVIMED